Drug repositioning

Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics

Retrieved on:

Thursday, October 5, 2023

The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.

Key Points:

The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.
Using the Olink Explore platform, researchers measured around 3,000 proteins in more than 54,000 UKB participant samples.
The findings illustrate the immense value of proteogenomics in elucidating biological mechanisms, identifying actionable new biomarkers, and accelerating drug development efforts.
“These landmark publications are a powerful demonstration of how next-gen proteomics can reveal crucial biological insights not seen with traditional genomics alone.

STALICLA Awarded EUR 1.7 Million to Lead Computational Drug Repositioning Activities in EU-funded REPO4EU Project

Retrieved on:

Tuesday, July 19, 2022

STALICLA DDS was granted a EUR 1.7 million budget over 6 years to act as leader for in silico drug repositioning work tasks.

Key Points:

STALICLA DDS was granted a EUR 1.7 million budget over 6 years to act as leader for in silico drug repositioning work tasks.
STALICLA DDS will bring its technology and know-how to analyze biosample and clinical data from hundreds of patients with neurodevelopmental disorders (NDDs).
Lynn DURHAM, STALICLAs CEO stated that STALICLA is thrilled to be leading the REPO4EU in silico drug repositioning work task project.
Repositioning investigational medicinal products beyond their original pursued indication is an efficient strategy to reduce timelines, costs and attrition in drug development.

Biotech Partnership to Accelerate Understanding of Genetics of Long Covid and Help Identify New Treatments

Retrieved on:

Wednesday, May 11, 2022

The project will include analysis of Sano Genetics data from 3,000 UK adults suffering from long COVID symptoms using PrecisionLifes proprietary combinatorial analytics platform to identify risk-factors and potential drug targets.

Key Points:

The project will include analysis of Sano Genetics data from 3,000 UK adults suffering from long COVID symptoms using PrecisionLifes proprietary combinatorial analytics platform to identify risk-factors and potential drug targets.
Under the agreement, Sano Genetics will provide access to its long COVID patient population dataset to PrecisionLife for analysis.
Understanding how our genetics influence our response to COVID-19 is key to better protecting vulnerable people and developing effective treatments.
Sano Genetics has been awarded 133,000 by Innovate UK to offer Long COVID patients free DNA testing kits they can use at home.

ZS acquires bioinformatics and systems biology company, Intomics A/S

Retrieved on:

Wednesday, May 4, 2022

The global professional services firm ZS announced today that it has acquired Danish bioinformatics and systems biology company, Intomics .

Key Points:

The global professional services firm ZS announced today that it has acquired Danish bioinformatics and systems biology company, Intomics .
Founded in Copenhagen, Denmark in 2008, Intomics accelerates and optimizes pharmaceutical drug discovery and development by enabling complex analysis of biomedical data.
As the pharmaceutical industry intensifies its efforts on developing novel drugs, demand for innovative capabilities in discovery and disease biology is growing.
Intomics was founded by world-leading scientists within the field of bioinformatics and systems biology to accelerate and improve drug discovery and development.

$2.07 Billion Global Immunohistochemistry Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on:

Wednesday, January 12, 2022

The emergence of various advanced techniques, such as multiplex IHC, computational pathology, and next-generation IHC, is driving the market for immunohistochemistry.

Key Points:

The emergence of various advanced techniques, such as multiplex IHC, computational pathology, and next-generation IHC, is driving the market for immunohistochemistry.
IHC protocols have gained popularity in the field of clinical pathology, especially in the subspecialties of oncologic pathology, hematopathology, and neuropathology.
Thus, the growing prevalence of cancer is expected to increase the demand for immunohistochemistry, thus contributing to the market growth.
Increasing regulatory approvals and the launch of novel IHC solutions in China are accelerating the country's market growth

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs

Retrieved on:

Monday, September 13, 2021

On July 29, 2021 and August 24, 2021 , respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinsons disease (PD) and MLR-1023 for Type 1 diabetes.

Key Points:

On July 29, 2021 and August 24, 2021 , respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinsons disease (PD) and MLR-1023 for Type 1 diabetes.
Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients.
A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate

Retrieved on:

Thursday, July 29, 2021

Melior Discovery, Health care, Melior, Health sciences, Health, Pharmaceutical industry in China, Drug repositioning

To the best of either companies knowledge, MLR-1019 will be the only drug candidate in development that addresses both movement (e.g., facial masking, dyskinesia, etc.)

Key Points:

To the best of either companies knowledge, MLR-1019 will be the only drug candidate in development that addresses both movement (e.g., facial masking, dyskinesia, etc.)
Melior Discovery and its companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE platform comprised of multiplexed in vivo disease models.
Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .
A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease

Retrieved on:

Monday, June 7, 2021

Melior Discovery, Melior, Health care, Health sciences, Health, Drug repositioning, Pharmaceutical industry in China

Melior Pharma 2 was spun-out of Melior Discovery (Melior), an in vivo pharmacology-focused biopharmaceutical company, specifically for the purpose of advancing MLR-1019 for PD.

Key Points:

Melior Pharma 2 was spun-out of Melior Discovery (Melior), an in vivo pharmacology-focused biopharmaceutical company, specifically for the purpose of advancing MLR-1019 for PD.
The Company has signed a Letter of Intent to acquire MLR-1019 (armesocarb) for Parkinsons Disease from Melior Pharmaceuticals II, LLC and is actively exploring additional pipeline additions.
Melior Discovery and its sister companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE platform comprised of multiplexed in vivo disease models.
A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics

Retrieved on:

Monday, June 7, 2021

Biotechnology, Pharmaceutical, Health, Clinical trials, Melior Discovery, Melior, Drug repositioning, Health care, Health sciences, Life sciences, Melior, Adhera Therapeutics, MELIOR, ADHERA THERAPEUTICS

Melior Pharmaceuticals (Melior) announced that it has signed a letter of intent with Adhera Therapeutics, Inc .

Key Points:

Melior Pharmaceuticals (Melior) announced that it has signed a letter of intent with Adhera Therapeutics, Inc .
(OTCPK: ATRX; Adhera) for the acquisition of Meliors Parkinsons disease (PD) candidate, MLR-1019 (armesocarb).
Melior Discovery and its sister companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE platform comprised of multiplexed in vivo disease models.
Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .

Hyundai Bioscience leads in the repurposing of Niclosamide

Retrieved on:

Thursday, April 8, 2021

Anthelmintics, Chloroarenes, Salicylanilides, Niclosamide, Nitrobenzenes, Pesticides, Hyundai Motor Company, Drug repositioning, Repurposing, Articles, Drugs, Health sciences

CNPharm also filed international patent applications on this DDS technology for repurposing Niclosamide as COVID-19 treatment.

Key Points:

CNPharm also filed international patent applications on this DDS technology for repurposing Niclosamide as COVID-19 treatment.
This means that the international pharmaceutical community has recognized that CNPharm, the parent company of Hyundai Bioscience, is leading the way to repurpose the anthelmintic drug.
An official at Hyundai Bioscience stated that this is the first time that Niclosamide's bioavailability improvement for drug repurposing has been published in an international journal.
Based on CNPharm's original technology, Hyundai Bioscience has dramatically improved the absorption rate and half-life of Niclosamide last year, developing CP-COV03, an oral treatment for COVID-19.